Photoaffinity ligand of Cystic Fibrosis corrector VX-445 identifies SCCPDH as an off-target
Cystic fibrosis (CF) pharmacological correctors improve Cystic Fibrosis transmembrane conductance regulator (CFTR) protein trafficking and function. Several side-effects from these correctors and adverse drug interactions have been reported, emphasizing the need to understand off-targets. We synthesized VU439, a functionalized photoaffinity ligand (PAL) of VX-445. Chemoproteomics analysis by mass spectrometry (MS) was used to identify crosslinked proteins in CF bronchial epithelial cells expressing F508del CFTR. We identified saccharopine dehydrogenase-like oxidoreductase (SCCPDH), an uncharacterized putative oxidoreductase, as a VX-445 specific off-target. We then characterized changes in the metabolomic profiles of cells overexpressing SCCPDH to determine the consequence of VX-445 binding to SCCPDH. These data show dysregulation of amino acid metabolism and a potential inhibitory activity of VX-445 on SCCPDH. The identified off-target may explain exacerbation of psychological symptoms observed in the clinic, thus emphasizing the need for further optimization of correctors.